Nasoferm Mentol (Xylometazoline Hydrochloride)

Xylometazoline, the active ingredient in Nasoferm Mentol, is an alpha‑adrenergic agonist presented as a nasal spray for topical nasal use. It relieves nasal congestion associated with the common cold, sinusitis and allergic rhinitis in adults and children.

GNH USA supplies Nasoferm Mentol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline is used as a topical nasal decongestant to reduce swelling of the nasal mucosa in several upper‑respiratory conditions.

- Common cold: alleviates nasal blockage and improves airflow. - Sinusitis: reduces mucosal edema, facilitating sinus drainage. - Allergic rhinitis: diminishes nasal obstruction caused by allergic inflammation.

Xylometazoline may cause local or systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation: mild burning or stinging. - Sneezing: transient increase in sneezing. - Dryness: dryness of the nasal mucosa. - Headache: mild headache.

Serious or Rare Side Effects: - Rebound congestion: worsening blockage after extended use. - Hypertension: elevated blood pressure in susceptible patients. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis.

When using Xylometazoline nasal spray, certain precautions help ensure safe and effective treatment.

- Duration of use: limit to no more than 3‑5 consecutive days to avoid rebound congestion. - Age restrictions: avoid use in children under 2 years unless advised by a healthcare professional. - Pre‑existing conditions: use cautiously in patients with hypertension, cardiovascular disease, or thyroid disorders. - Drug interactions: consult a physician before combining with monoamine oxidase inhibitors or other vasoconstrictors. - Pregnancy and lactation: discuss potential risks with a healthcare provider before use. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight, and retain in original packaging.

Xylometazoline can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may increase risk of hypertensive episodes. - Other nasal decongestants: combined vasoconstriction can raise blood pressure excessively.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may reduce the effectiveness of blood pressure control. - Beta‑blockers: possible additive cardiovascular effects. - Tricyclic antidepressants: may enhance vasoconstrictive response.